Modified release pharmaceutical formulation

Details Modified release pharmaceutical formulation Modified release pharmaceutical formulation

2007-04-10

2007-04-10

Woodward, Michael P. (Department: 1615)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S210100, C514S183000, C514S781000

Reexamination Certificate

active

10516420

ABSTRACT:
A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1represents C?1-2#191 alkyl substituted by one or more fluoro substituents; R2represents hydrogen, hydroxy, methoxy or ethoxy; and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier, provided that the formulation may only contain iota-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder

REFERENCES:
patent: 4346078 (1982-08-01), Bajusz et al.
patent: 4792452 (1988-12-01), Howard et al.
patent: 5498724 (1996-03-01), Nystrom et al.
patent: 5559232 (1996-09-01), Ackermann et al.
patent: 5602253 (1997-02-01), Antonsson et al.
patent: 5659071 (1997-08-01), Nystrom et al.
patent: 5705487 (1998-01-01), Schacht et al.
patent: 5707966 (1998-01-01), Schacht et al.
patent: 5710130 (1998-01-01), Schacht et al.
patent: 5723444 (1998-03-01), Antonsson et al.
patent: 5744487 (1998-04-01), Ohshima et al.
patent: 5780631 (1998-07-01), Antonsson et al.
patent: 5783563 (1998-07-01), Antonsson et al.
patent: 5856307 (1999-01-01), Antonsson et al.
patent: 5939392 (1999-08-01), Antonsson et al.
patent: 5965692 (1999-10-01), Gustafsson et al.
patent: 6030972 (2000-02-01), Bohm et al.
patent: 6051568 (2000-04-01), Gustafsson et al.
patent: 6221898 (2001-04-01), Antonsson
patent: 6225287 (2001-05-01), Edvardsson et al.
patent: 6262028 (2001-07-01), Antonsson et al.
patent: 6265397 (2001-07-01), Karlsson et al.
patent: 6440937 (2002-08-01), Baucke et al.
patent: 6440939 (2002-08-01), Edvardsson et al.
patent: 6444817 (2002-09-01), Bohm et al.
patent: 6455671 (2002-09-01), Bohm et al.
patent: 6479078 (2002-11-01), Hedstrom et al.
patent: 6521253 (2003-02-01), Forsman et al.
patent: 6576245 (2003-06-01), Lundgren et al.
patent: 6576657 (2003-06-01), Karlsson et al.
patent: 6599894 (2003-07-01), Inghardt et al.
patent: 6660279 (2003-12-01), Lundgren et al.
patent: 6716834 (2004-04-01), Andersson et al.
patent: 6750243 (2004-06-01), Inghardt et al.
patent: 6875446 (2005-04-01), Forsman et al.
patent: 6888007 (2005-05-01), Edvardsson et al.
patent: 6921758 (2005-07-01), Gustafsson et al.
patent: 6984627 (2006-01-01), Antonsson et al.
patent: 6998136 (2006-02-01), Lundgren et al.
patent: 7056907 (2006-06-01), Inghardt et al.
patent: 2004/0019033 (2004-01-01), Inghardt et al.
patent: 2004/0242492 (2004-12-01), Inghardt et al.
patent: 0185390 (1991-10-01), None
patent: 0526877 (1993-02-01), None
patent: 0293881 (1993-03-01), None
patent: 0530167 (1993-03-01), None
patent: 0539059 (1993-04-01), None
patent: 0195212 (1993-11-01), None
patent: 0468231 (1994-09-01), None
patent: 0641779 (1995-03-01), None
patent: 0648780 (1995-04-01), None
patent: 0362002 (1995-07-01), None
patent: 0686642 (1995-12-01), None
patent: 0364344 (1998-05-01), None
patent: 0542525 (1998-07-01), None
patent: 0559046 (2001-07-01), None
patent: 0669317 (2002-09-01), None
patent: 0773955 (2003-04-01), None
patent: 0672658 (2003-09-01), None
patent: 57149217 (1982-09-01), None
patent: WO 93/11152 (1993-06-01), None
patent: WO 93/18060 (1993-09-01), None
patent: WO 94/29269 (1994-12-01), None
patent: WO 94/29336 (1994-12-01), None
patent: WO 95/23609 (1995-09-01), None
patent: WO 95/35309 (1995-12-01), None
patent: WO 96/03374 (1996-02-01), None
patent: WO 96/25426 (1996-08-01), None
patent: WO 96/26717 (1996-09-01), None
patent: WO 96/31504 (1996-10-01), None
patent: WO 96/32110 (1996-10-01), None
patent: WO 97/02284 (1997-01-01), None
patent: WO 97/23499 (1997-07-01), None
patent: WO 97/39770 (1997-10-01), None
patent: WO 97/46577 (1997-12-01), None
patent: WO 97/49404 (1997-12-01), None
patent: WO 98/01422 (1998-01-01), None
patent: WO 98/06740 (1998-02-01), None
patent: WO 98/16252 (1998-04-01), None
patent: WO 98/57932 (1998-12-01), None
patent: WO 99/21586 (1999-05-01), None
patent: WO 99/29305 (1999-06-01), None
patent: WO 99/29664 (1999-06-01), None
patent: WO 99/39698 (1999-08-01), None
patent: WO 00/12043 (2000-03-01), None
patent: WO 00/13671 (2000-03-01), None
patent: WO 00/13710 (2000-03-01), None
patent: WO 00/14110 (2000-03-01), None
patent: WO 00/35869 (2000-06-01), None
patent: WO 00/42059 (2000-07-01), None
patent: WO 01/02426 (2001-01-01), None
patent: WO 01/87879 (2001-11-01), None
patent: WO 02/14270 (2002-02-01), None
patent: WO 02/19990 (2002-03-01), None
patent: WO 02/44145 (2002-06-01), None
patent: WO 03/000293 (2003-01-01), None
patent: WO 03/018551 (2003-03-01), None
patent: WO 03/101423 (2003-12-01), None
patent: WO 03/101957 (2003-12-01), None
Bonferoni et al. Journal of Controlled Release 30 (1994) 175-182.
CAS RN 30318-53-4 Nov. 2000.
CAS RN 192939-72-3 Aug. 1997□□.
CAS RN 159776-70-2 Dec. 1994.
Baveja et al. “Zero-order release hydrophilic matrix tablets of beta-adrenergic blockers” International Journal of Pharmaceutics 39:39-45 (1987).
Bonferoni et al. “On the employment of lambda-carrageenan in a matrix system. II. Lambda-Carrageenan and hydroxypropylmethylcellulose mixtures” J. Controlled Release 30:175-182 (1994).
Ham-Yong Park et al. “Effect of pH on Drug Release From Polysaccharide Tablets” Drug Delivery 5:13-18 (1998).
Picker “The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets” European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999).
Talukdar et al. “In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation” International Journal of Pharmaceutics 169(1):105-113 (1998).

Affiliated with

Also associated with

Rating

Modified release pharmaceutical formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified release pharmaceutical formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified release pharmaceutical formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3726778